Lobe Sciences Ltd. logo

Lobe Sciences Ltd. (LOBE)

Market Closed
27 May, 19:42
NEO-L NEO-L
CNSX CNSX Primary OTC PINK OTC PINK
NEO-L NEO-L
CA$
0. 1200
-0.025
-17.24%
CA$
- Market Cap
- P/E Ratio
- Div Yield
11,000 Volume
0 Eps
CA$ 0.145
Previous Close
Add Transaction
Day Range
0.12 0.12
Year Range
0.045 0.145
Want to track LOBE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

LOBE closed Wednesday lower at CA$0.12, a decrease of -17.24% from Tuesday's close, completing a monthly decrease of -4% or -CA$0.01. Over the past 12 months, LOBE stock gained 20%.
LOBE is not paying dividends to its shareholders.
The last earnings report, released on Apr 27, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Lobe Sciences Ltd. has completed 2 stock splits, with the recent split occurring on Jun 10, 2022.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on CNSX (CAD).

LOBE Chart

No Data

Lobe Sciences Ltd. (LOBE) FAQ

What is the stock price today?

The current price is CA$0.1200.

On which exchange is it traded?

Lobe Sciences Ltd. is listed on NEO-L.

What is its stock symbol?

The ticker symbol is LOBE.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Lobe Sciences Ltd. ever had a stock split?

Lobe Sciences Ltd. had 2 splits and the recent split was on Jun 10, 2022.

Lobe Sciences Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Frederick Dominick Sancilio CEO
NEO-L Exchange
CA53946V2066 ISIN
CA Country
- Employees
- Last Dividend
10 Jun 2022 Last Split
- IPO Date

Overview

Lobe Sciences Ltd. is a pioneering biopharmaceutical entity dedicated to harnessing the potential of proprietary psychedelic substances with the aim of advancing brain health, mental wellness, and overall cognitive function. The company operates at the forefront of a burgeoning field of medicine that seeks to leverage sub-hallucinogenic dosages of psychedelic compounds to address a variety of neurological and psychiatric conditions. Initially known as Greenstar Biosciences Corp., the organization underwent a significant rebranding in November 2020, emerging as Lobe Sciences Ltd., to better reflect its focused mission and expanding research endeavors. With its headquarters firmly established in Vancouver, Canada, Lobe Sciences Ltd. represents a blend of innovative research and steadfast dedication to finding novel solutions within the health and wellness landscape.

Products and Services

  • Research and Development in Psychedelic Compounds

    At the core of Lobe Sciences Ltd.'s operations is its intensive research and development efforts surrounding psychedelic substances. These endeavors are targeted at uncovering and harnessing the therapeutic potential of sub-hallucinatory doses of these compounds. The ultimate goal is to develop treatments that can significantly improve mental health outcomes, enhance cognitive abilities, and foster an overall state of wellness in individuals facing neurological and psychiatric challenges.

Contact Information

Address: 1199 West Hastings Street
Phone: 949-505-5623
Download app banner
Blog Affiliate Program About Terms Privacy Help Contact Us
2026 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark